Evotec stock falls 2.1 percent as Q2 revenue drops 16.21 percent

Published on 10/07/2026 at 14:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock stood at EUR 2.88 on October 7, 2026, after a 2.1 percent Xetra decline. Q2 revenue fell 16.21 percent to EUR 143.48 million.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Pop-Art-Comic-Szene mit Wissenschaftler und Reagenzglas symbolisiert lebendig die Forschungswelt von Evotec SE, ISIN DE0005664809, Illustration mit AI erstellt.

Evotec SE stock (ISIN DE0005664809) traded at EUR 2.88 in Xetra trading on October 7, 2026, down 2.1 percent during the session. The move keeps the biotech company close to its 52-week low while investors assess weaker quarterly revenue and a sharply reduced full-year outlook.

Revenue falls in the second quarter

finanzen.ch reported that Evotec posted Q2 2026 revenue of EUR 143.48 million for the quarter ended June 30, 2026. Revenue fell 16.21 percent from EUR 171.24 million in the prior-year quarter, while earnings per share stood at negative EUR 0.26 compared with negative EUR 0.24 a year earlier.

The latest quarter therefore combines a double-digit revenue decline with a deeper per-share loss. The operating result was negative EUR 113.273 million in Q2 2026, according to the standardized quarterly figures for the period.

Guidance frames the investment case

Börse Express reported that Evotec cut its FY2026 revenue guidance to EUR 570 million-610 million from EUR 700 million-780 million. Adjusted EBITDA guidance moved to a loss of EUR 70 million-105 million from the previous range of positive EUR 0 million-40 million.

The transformation program Horizon is intended to deliver EUR 75 million in annual savings by the end of 2027. That target gives the stock a measurable execution test, because cost reductions must offset weaker sales conversion and the latest operating losses.

Consensus remains above the share price

The analyst overview published by Börse Express listed one Buy, three Holds and zero Sells across four research houses, with a 12-month consensus target of EUR 3.80 and an indicated upside of 30.0 percent. The consensus is a market expectation, not a guarantee of future performance.

Evotec also faces a management transition. According to EQS Group on September 29, 2026, Chief Scientific Officer Cord Dohrmann left the role on September 30, 2026, and the company began searching for a successor.

Stock stays near the yearly low

Evotec stock was EUR 0.17 above its 52-week low of EUR 2.71 on October 7, 2026, while the 52-week high stood at EUR 7.30. The distance to the low is smaller than the operational gap shown by the latest revenue and guidance figures.